TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3126634

Group type: EXPERIMENTAL
Intervention: Transdermal nitroglycerin (NTG) 10 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Transdermal nitroglycerin (NTG) 5 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 31410887

Group type: EXPERIMENTAL
Intervention: Active-Start intervention (before-school physical activity program for 8 weeks)
Number of subjects: 170
Study: 30217412

Group type: EXPERIMENTAL
Intervention: Oncology rehabilitation with motivational interviewing delivered once weekly for 7 weeks via telephone by a physiotherapist
Number of subjects: 46

Group type: COMPARATOR
Intervention: Oncology rehabilitation
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Oncology rehabilitation with motivational interviewing
Number of subjects: 46
Study: 28218557

Group type: EXPERIMENTAL
Intervention: Trial 2C (surgical procedure for primary palatal repair)
Number of subjects: 448

Group type: EXPERIMENTAL
Intervention: Trial 3D (surgical procedure for primary palatal repair)
Number of subjects: 448

Group type: EXPERIMENTAL
Intervention: Trial 3A (surgical procedure for primary palatal repair)
Number of subjects: 448
Study: 26187456

Group type: EXPERIMENTAL
Intervention: Dronabinol 30 mg/d
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Participants who smoked marijuana
Number of subjects: 60
Study: 23725999

Group type: EXPERIMENTAL
Intervention: Everolimus (10 mg/d) with concurrent radiation (60 Gy in 30 fractions) and temozolomide (75 mg/m2 per day)
Number of subjects: 25
Study: 20979460

Group type: EXPERIMENTAL
Intervention: Acupressure (eight treatments over 4 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 0
Study: 18779665

Group type: EXPERIMENTAL
Intervention: Punctal plugs
Number of subjects: 19

Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 19
Study: 16957130

Group type: EXPERIMENTAL
Intervention: Patients on dopamine agonists
Number of subjects: 297

Group type: COMPARATOR
Intervention: Patients not specified as on dopamine agonists
Number of subjects: 297
Study: 12562338

Group type: EXPERIMENTAL
Intervention: Wax epilation followed by long-pulsed alexandrite laser treatment
Number of subjects: 13

Group type: COMPARATOR
Intervention: Unwaxed control areas
Number of subjects: 13
Study: 10604304

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 164
Study: 9104855

Group type: EXPERIMENTAL
Intervention: High-Carbohydrate (Hi-CHO; 83% of energy)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: High-Fat (Hi-Fat; 68% of energy)
Number of subjects: 7
Study: 7880221

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Active medications and surgery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Placebo effects
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Placebo effects plus disease natural history and regression to the mean
Number of subjects: 0
Study: 2743378

Group type: EXPERIMENTAL
Intervention: Metronidazole (MN) applied to dentinal lesions covered by alpha‐tricalcium phosphate (TCP) cement for 1 day, 1 month, 1 year, and/or 2 years in vivo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (TCP cement without MN)
Number of subjects: 0
Study: 938705

Group type: EXPERIMENTAL
Intervention: High-information stimuli (12, 26, or 60 bits of information)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Long-duration stimuli (4.5 sec)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Low-information stimuli (12, 26, or 60 bits of information)
Number of subjects: 90
Study: 31780332

Group type: EXPERIMENTAL
Intervention: Penile prosthesis implantation without dilatation of the corpora cavernosa (n=80)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Penile prosthesis implantation with dilatation of the corpora cavernosa
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Overall satisfaction reported
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Complications reported
Number of subjects: 120
Study: 31240587

Group type: EXPERIMENTAL
Intervention: Mixed Martial Arts (MMA) intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waitlist control (WLC) group
Number of subjects: 0
Study: 28873062

Group type: EXPERIMENTAL
Intervention: 2% Lidocaine irrigation
Number of subjects: 84

Group type: COMPARATOR
Intervention: Saline irrigation
Number of subjects: 84
Study: 26218726

Group type: EXPERIMENTAL
Intervention: Continuous 5-0 nylon sutures
Number of subjects: 105

Group type: COMPARATOR
Intervention: Interrupted 5-0 nylon sutures
Number of subjects: 105
Study: 23835715

Group type: EXPERIMENTAL
Intervention: Obinutuzumab (GA101) 1,600/800 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Obinutuzumab (GA101) 400/400 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 40
Study: 22308802

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparins
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fondaparinux
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Medical thromboprophylaxis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 20190923

Group type: EXPERIMENTAL
Intervention: Blocking the initiation of practice on review steps
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Removing payment for practice initiated after prompts (extinction)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Persistently repeated the same step
Number of subjects: 0
Study: 16958565

Group type: COMPARATOR
Intervention: Risperidone (0.25-4.5 mg/day, mean dose 1.62 ± 1.02 mg/day)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Olanzapine (2.5-20 mg/day, mean dose 8.18 ± 4.41 mg/day)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Both treatments (Risperidone and Olanzapine)
Number of subjects: 25
Study: 15041031

Group type: COMPARATOR
Intervention: Fatty acid treatment
Number of subjects: 0
Study: 10930796

Group type: EXPERIMENTAL
Intervention: Doxorubicin
Number of subjects: 294

Group type: COMPARATOR
Intervention: Paclitaxel
Number of subjects: 294
Study: 7627087

Group type: EXPERIMENTAL
Intervention: Micronutrient supplementation (vitamin A, riboflavin, zinc, selenium)
Number of subjects: 298

Group type: COMPARATOR
Intervention: Placebo (lactose capsule)
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: Micronutrient supplementation
Number of subjects: 298

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 298
Study: 1645825

Group type: COMPARATOR
Intervention: Mixed bacterial vaccine (MBV) in Series 1
Number of subjects: 86

Group type: COMPARATOR
Intervention: Mixed bacterial vaccine (MBV) in Series 2
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Mixed bacterial vaccine (MBV)
Number of subjects: 86
Study: 7014286

Group type: EXPERIMENTAL
Intervention: Selsun Blue
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Head & Shoulders
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Flex
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Tegrin
Number of subjects: 199
Study: 31796477

Group type: EXPERIMENTAL
Intervention: Coupled Plasma Filtration and Adsorption (CPFA)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 49
Study: 28367037

Group type: EXPERIMENTAL
Intervention: Topical sodium diclofenac 0.1%
Number of subjects: 100

Group type: COMPARATOR
Intervention: Artificial tear drop (placebo)
Number of subjects: 100
Study: 26114901

Group type: EXPERIMENTAL
Intervention: Computerized cognitive training
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 42
Study: 24099839

Group type: EXPERIMENTAL
Intervention: Intravenous iron sucrose (200mg immediately after each chemotherapy infusion)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Oral ferrous fumarate (200mg three times a day)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Intravenous iron sucrose
Number of subjects: 64

Group type: COMPARATOR
Intervention: Oral ferrous fumarate
Number of subjects: 64
Study: 21341889

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT) for PTSD and depressive symptoms
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 150
Study: 19382089

Group type: EXPERIMENTAL
Intervention: High-efficiency hemodialysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-flux hemodialysis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low-flux hemodialysis
Number of subjects: 0
Study: 17607425

Group type: EXPERIMENTAL
Intervention: Subjects with RRMS
Number of subjects: 115

Group type: COMPARATOR
Intervention: Health controls
Number of subjects: 115
Study: 15448447

Group type: EXPERIMENTAL
Intervention: A-V Impulse system
Number of subjects: 64

Group type: COMPARATOR
Intervention: Elevation and plaster (Control)
Number of subjects: 64
Study: 11447072

Group type: EXPERIMENTAL
Intervention: Myocardial tissue Doppler (TD) imaging
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group (age- and sex-matched)
Number of subjects: 43
Study: 9727727

Group type: EXPERIMENTAL
Intervention: Paroxetine 20 mg plus Pindolol 7.5 mg
Number of subjects: 80

Group type: COMPARATOR
Intervention: Paroxetine 20 mg plus Placebo
Number of subjects: 80
Study: 9836512

Group type: EXPERIMENTAL
Intervention: Insulin 0.25 mU x kg(‐1) x min(‐1)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Insulin 0.5 mU x kg(‐1) x min(‐1)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Insulin 1.0 mU x kg(‐1) x min(‐1)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Insulin (all dosages)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 24
Study: 2501714

Group type: EXPERIMENTAL
Intervention: Ferric chondroitin sulfate (90 mg of iron)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Ferritin iron (91 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Comparison of ferric chondroitin sulfate vs ferritin iron
Number of subjects: 12
Study: 1018189

Group type: EXPERIMENTAL
Intervention: Bimedial recessions followed by bilateral rectus resections when needed
Number of subjects: 49

Group type: COMPARATOR
Intervention: Recession/resections performed initially and followed by the same procedure on the fellow eye
Number of subjects: 49
Study: 31370871

Group type: EXPERIMENTAL
Intervention: Blue-depleted evening light
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal lighting conditions
Number of subjects: 0
Study: 27798388

Group type: EXPERIMENTAL
Intervention: Office-based recall (Group B)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Outsourced recall (Group C)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Usual care (Group A)
Number of subjects: 87
Study: 26173554

Group type: COMPARATOR
Intervention: Mailed toolkit delivery (minimal intensity)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Mailed toolkit delivery with quarterly audit and feedback reports (moderate intensity)
Number of subjects: 42

Group type: COMPARATOR
Intervention: In-person toolkit delivery with academic detailing, on-site behavioral management training, and quarterly audit and feedback reports (high intensity)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: All groups (comparison of prescribing levels)
Number of subjects: 42
Study: 23941549

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.6 μg/kg/h continuous infusion)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Saline (0.9% sodium chloride for injection, maintenance infusion)
Number of subjects: 20
Study: 21304097

Group type: EXPERIMENTAL
Intervention: Symptom onset-to-balloon time <3 hours
Number of subjects: 5745

Group type: EXPERIMENTAL
Intervention: Symptom onset-to-balloon time 3 to 5 hours
Number of subjects: 5745

Group type: EXPERIMENTAL
Intervention: Symptom onset-to-balloon time >5 hours
Number of subjects: 5745

Group type: EXPERIMENTAL
Intervention: Door-to-balloon time <60 minutes
Number of subjects: 5745

Group type: EXPERIMENTAL
Intervention: Door-to-balloon time 60 to 90 minutes
Number of subjects: 5745

Group type: EXPERIMENTAL
Intervention: Door-to-balloon time 90 to 120 minutes
Number of subjects: 5745

Group type: EXPERIMENTAL
Intervention: Door-to-balloon time ≥120 minutes
Number of subjects: 5745
Study: 19396417

Group type: EXPERIMENTAL
Intervention: Long-term psychoanalysis (defined as fewer than 50 treatment sessions)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Psychodynamic short-term interventions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cognitive interventions
Number of subjects: 0
Study: 16708040

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral intervention (10-contact, 18-week duration)
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral intervention
Number of subjects: 237

Group type: COMPARATOR
Intervention: Conventional care (control group)
Number of subjects: 237
Study: 15329210

Group type: EXPERIMENTAL
Intervention: Pegasys (180 microg injection once a week for 24 weeks)
Number of subjects: 197

Group type: COMPARATOR
Intervention: Roferon-A (3 MU injection three times a week for 24 weeks)
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: HCV genotype
Number of subjects: 197
Study: 11532743

Group type: EXPERIMENTAL
Intervention: Piribedil
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 9863112

Group type: EXPERIMENTAL
Intervention: Integrated traditional Chinese and Western medicine (TCM‐WM)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Western medicine alone
Number of subjects: 146
Study: 8322986

Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 57

Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 57
Study: 3535552

Group type: EXPERIMENTAL
Intervention: Single dose piperacillin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Triple dose cefoxitin
Number of subjects: 0
Study: 29955115

Group type: EXPERIMENTAL
Intervention: Risperidone treatment in ASD patients
Number of subjects: 84
Study: 27286179

Group type: EXPERIMENTAL
Intervention: Hot condition (34.5°C)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Thermoneutral condition (20°C)
Number of subjects: 10
Study: 25085771

Group type: COMPARATOR
Intervention: Standard treatment (positive control)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Targeted selective treatment (TST)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Both groups (control and TST)
Number of subjects: 88
Study: 22445779

Group type: EXPERIMENTAL
Intervention: Chewing gum for 5 min (Time 1: T1)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Keeping the jaw relaxed for 5 min (Time 2: T2)
Number of subjects: 14
Study: 19398787

Group type: EXPERIMENTAL
Intervention: Diluted povidone-iodine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Half-pin fixation
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Wire fixation
Number of subjects: 60
Study: 17533176

Group type: EXPERIMENTAL
Intervention: Lucinactant
Number of subjects: 1546

Group type: COMPARATOR
Intervention: Colfosceril
Number of subjects: 1546

Group type: COMPARATOR
Intervention: Beractant
Number of subjects: 1546

Group type: COMPARATOR
Intervention: Poractant alfa
Number of subjects: 1546

Group type: COMPARATOR
Intervention: Animal-derived surfactants (beractant and poractant)
Number of subjects: 1546
Study: 15768833

Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 104
Study: 11472451

Group type: EXPERIMENTAL
Intervention: Repaglinide, 1‐4 mg at mealtimes
Number of subjects: 256

Group type: COMPARATOR
Intervention: Glipizide, 5‐15 mg daily
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Overall results
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Minor hypoglycaemia
Number of subjects: 256
Study: 9509197

Group type: EXPERIMENTAL
Intervention: alpha-stat acid-base management
Number of subjects: 20

Group type: COMPARATOR
Intervention: pH-stat acid-base management
Number of subjects: 20
Study: 7823337

Group type: EXPERIMENTAL
Intervention: Transvaginal sonography
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Hysteroscopy
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Transvaginal sonography with endometrial thickness of 8 mm
Number of subjects: 51

Group type: COMPARATOR
Intervention: Dilatation and curettage (gold standard)
Number of subjects: 51
Study: 3292303

Group type: EXPERIMENTAL
Intervention: Acarbose (n = 15)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo (n = 13)
Number of subjects: 28
Study: 6451461

Group type: EXPERIMENTAL
Intervention: DS 103-282 (5 mg, three times daily for 7 days)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Diazepam (5 mg, three times daily for 7 days)
Number of subjects: 30
Study: 31999308

Group type: EXPERIMENTAL
Intervention: SNORE Utility Index (developed from SF-6D utility index)
Number of subjects: 500
Study: 31692553

Group type: EXPERIMENTAL
Intervention: Moxifloxacin orally for 6 days
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control group (no antibiotic treatment)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: PPM positive group
Number of subjects: 96

Group type: COMPARATOR
Intervention: PPM negative group
Number of subjects: 96
Study: 27908227

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (10,000 IU soft gels administered three times per week)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Placebo (vitamin A soft gels devoid of active ingredients administered thrice weekly)
Number of subjects: 152
Study: 25015398

Group type: EXPERIMENTAL
Intervention: Liver segmentation and MRI-based PDFF estimation
Number of subjects: 43
Study: 25117183

Group type: EXPERIMENTAL
Intervention: Vandetanib + Metformin 1000 mg
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Vandetanib + Digoxin 0.25 mg
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Vandetanib + Midazolam 7.5 mg
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Vandetanib + Omeprazole 40 mg
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Vandetanib + Ranitidine 150 mg
Number of subjects: 79
Study: 20842517

Group type: EXPERIMENTAL
Intervention: Er,Cr:YSGG laser
Number of subjects: 40

Group type: COMPARATOR
Intervention: CVD bur
Number of subjects: 40

Group type: COMPARATOR
Intervention: Diamond bur
Number of subjects: 40

Group type: COMPARATOR
Intervention: Carbide bur
Number of subjects: 40
Study: 19251685

Group type: EXPERIMENTAL
Intervention: Stratified program designed to correct initial movement errors
Number of subjects: 173

Group type: COMPARATOR
Intervention: Generalized program with the same exercises for all
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: High school subjects
Number of subjects: 173

Group type: COMPARATOR
Intervention: Pre-high school subjects
Number of subjects: 173
Study: 17479946

Group type: EXPERIMENTAL
Intervention: SQV-RTV-ATV regimen (1500 mg saquinavir, 100 mg ritonavir, 300 mg atazanavir once per day without NRTIs)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: SQV-RTV-ATV regimen
Number of subjects: 25

Group type: COMPARATOR
Intervention: SQV formulations (200 mg vs. 500 mg)
Number of subjects: 25
Study: 15841774

Group type: EXPERIMENTAL
Intervention: Skin-to-skin contact immediately after birth
Number of subjects: 60

Group type: COMPARATOR
Intervention: No skin-to-skin contact
Number of subjects: 60
Study: 12365904

Group type: EXPERIMENTAL
Intervention: Laser trabeculoplasty plus topical betaxolol hydrochloride (n = 129)
Number of subjects: 255

Group type: COMPARATOR
Intervention: No initial treatment (n = 126)
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Laser trabeculoplasty plus topical betaxolol hydrochloride
Number of subjects: 255
Study: 9672331

Group type: EXPERIMENTAL
Intervention: 60‐s inflation duration (group A)
Number of subjects: 81

Group type: COMPARATOR
Intervention: 6‐s inflation duration (group B)
Number of subjects: 81
Study: 7978416

Group type: COMPARATOR
Intervention: ondansetron plus saline (Group 1)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: ondansetron plus dexamethasone (Group 2)
Number of subjects: 180
Study: 2726279

Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg + 20 mg codeine
Number of subjects: 25

Group type: COMPARATOR
Intervention: Ibuprofen 400 mg
Number of subjects: 25
Study: 820357

Group type: EXPERIMENTAL
Intervention: Synthetic thyrotrophin releasing factor (TRF, Ro 08‐6270) administered via rapid i.v. injection
Number of subjects: 20

Group type: COMPARATOR
Intervention: Solvent only (placebo)
Number of subjects: 20
Study: 31898636

Group type: EXPERIMENTAL
Intervention: Lichen Planus Severity Index (LPSI) used by 21 dermatologists scoring photographs of 4 patients.
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Lichen Planus Severity Index (LPSI) evaluated by 6 doctors on 10 real-world patients.
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Lichen Planus Severity Index (LPSI) compared with Physician Global Assessment score.
Number of subjects: 27
Study: 30591415

Group type: EXPERIMENTAL
Intervention: Alirocumab 150 mg Q2W
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Alirocumab 75 mg Q2W
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Alirocumab dose increase (from 75 to 150 mg Q2W)
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Treatment-emergent adverse events
Number of subjects: 214
Study: 29122148

Group type: EXPERIMENTAL
Intervention: Aerobic exercise (AE) for 12 weeks
Number of subjects: 56

Group type: COMPARATOR
Intervention: Health education (HE) for 12 weeks
Number of subjects: 56
Study: 26131612

Group type: EXPERIMENTAL
Intervention: Liuzijue Qigong (LQG) program consisting of four 45‐minute sessions each week and daily walking for 30 minutes for 6 months
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Liuzijue Qigong (LQG) program
Number of subjects: 126

Group type: COMPARATOR
Intervention: Control group walking daily for 30 minutes
Number of subjects: 126
Study: 23475405

Group type: EXPERIMENTAL
Intervention: Bimatoprost 0.01% (n = 56)
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Travoprost 0.004% (n = 53)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Latanoprost 0.005% (n = 55)
Number of subjects: 164
Study: 22071699

Group type: EXPERIMENTAL
Intervention: Dietary Glycemic Index (GI)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Dietary Glycemic Load (GL)
Number of subjects: 26
Study: 19361952

Group type: EXPERIMENTAL
Intervention: Atropine 0.5mg
Number of subjects: 333

Group type: EXPERIMENTAL
Intervention: Hyoscine butylbromide 20mg
Number of subjects: 333

Group type: EXPERIMENTAL
Intervention: Scopolamine 0.25mg
Number of subjects: 333
Study: 17725739

Group type: EXPERIMENTAL
Intervention: Discontinuous plasmapheresis
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control session (reclined position without plasma withdrawal)
Number of subjects: 60